You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東陽光藥(01558.HK):治療精神分裂症產品奧氮平片獲批准上市
格隆匯 09-28 16:45

格隆匯 9 月 28日丨東陽光藥(01558.HK)發佈公告,公司從廣東東陽光藥業有限公司收購的產品奧氮平片(5mg及10mg)已獲中國國家藥品監督管理局審批完畢並獲准上市。後續通過補充申請,該產品的上市許可持有人將變更為公司或公司的控股子公司。

根據披露,奧氮平主要用於治療精神分裂症,對奧氮平初次治療有效的患者,鞏固治療可以有效維持臨牀症狀改善。此外,奧氮平也適用於治療中到重度的躁狂發作,對治療有效的躁狂發作患者,奧氮平可以預防雙相情感障礙的復發。根據艾美仕中國市場數據,2019年奧氮平類藥物的銷售額約為2.87億美元,佔抗精神病藥物總銷售額的40.65%,其中,奧氮平片劑型於2019年的銷售額約為2.85億美元。

該產品獲批上市後即為視同通過仿製藥質量和療效一致性評價的產品,具有可觀的市場潛力。該產品的獲批上市進一步豐富了集團產品線,也將為患者提供更多質價雙優的用藥選擇。同時,集團也將持續推進新產品研發管線的進程,致力於補充尚未滿足的臨牀用藥需求。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account